Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Availability Heuristic01:08

The Availability Heuristic

7.2K
A heuristic is a general problem-solving framework (Tversky & Kahneman, 1974). You can think of these as mental shortcuts that are used to solve problems. Different types of heuristics are used in different types of situations, and the impulse to use a heuristic occurs when one of five conditions is met (Pratkanis, 1989):
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic screening of triple negative thrombocytosis patients identifies germline <i>MPL</i> compound mutations and <i>SH2B3/LNK</i> truncating mutations.

Haematologica·2026
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

The oncologist·2026
Same author

Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing.

bioRxiv : the preprint server for biology·2026
Same author

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control.

Therapeutic advances in hematology·2026
Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026

Related Experiment Video

Updated: Mar 16, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
12:33

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

48.7K

[Not Available].

Juliette Soret1, Jean-Jacques Kiladjian2

  • 1Centre d'Investigations Cliniques, Hôpital Saint-Louis, APHP, Paris, France.

Bulletin Du Cancer
|August 7, 2016
PubMed
Summary
This summary is machine-generated.

Ruxolitinib, a Janus Kinase (JAK) inhibitor, offers targeted therapy for myeloproliferative neoplasms like polycythemia vera and myelofibrosis. It effectively manages symptoms and improves outcomes in patients resistant to conventional treatments.

Keywords:
Inhibiteurs de JAK2JAK2 inhibitorsMyelofibrosisMyeloproliferativeMyélofibrosePolycythemia veraPolyglobulie de VaquezRuxolitinibSyndromesTargeted therapiesThérapies cibléesmyéloprolifératifsneoplasms

More Related Videos

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles
14:02

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

25.1K
A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos
07:29

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

22.8K

Related Experiment Videos

Last Updated: Mar 16, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
12:33

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

48.7K
Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles
14:02

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

25.1K
A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos
07:29

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

22.8K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The JAK2V617F mutation is a key driver in myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and myelofibrosis (MF).
  • Targeted therapies offer new treatment avenues for MPNs, addressing limitations of conventional management.

Purpose of the Study:

  • To review the role and efficacy of ruxolitinib, a Janus Kinase (JAK) inhibitor, in treating PV and MF.
  • To highlight ruxolitinib's impact on patient outcomes and symptom management in MPNs.

Main Methods:

  • Review of Phase 3 clinical trials (RESPONSE, COMFORT-I, COMFORT-II) evaluating ruxolitinib in PV and MF.
  • Analysis of ruxolitinib's efficacy in improving hematocrit control, reducing splenomegaly, alleviating symptoms, and enhancing survival.

Main Results:

  • Ruxolitinib demonstrated significant improvements in hematocrit control and symptom burden in PV patients resistant to hydroxyurea.
  • In MF patients, ruxolitinib effectively reduced spleen size, improved symptoms, and was associated with improved survival in intermediate/high-risk disease.

Conclusions:

  • Ruxolitinib is a valuable targeted therapy for specific patient populations with PV and MF, offering benefits beyond best available therapy.
  • Despite advancements, unmet needs remain in MPN treatment, including managing cytopenias and altering disease progression.